PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 11, 2004BMJ295 citationsOpen Access

Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study)

View Full Paper
MMMichel MarreMLMichel LièvreGCGilles Châtellier

Key Points

  • To evaluate the impact of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised urinary albumin.
  • Randomized, double-blind, placebo-controlled trial

Structured PICO

Does low dose (1.25 mg) ramipril once daily improve cardiovascular and renal outcomes in patients with type 2 diabetes and albuminuria?

P
Population
Patients with type 2 diabetes and raised excretion of urinary albumin (albuminuria)
I
Intervention
Low dose (1.25 mg) ramipril once daily
C
Comparator
Placebo
O
Outcome
Cardiovascular and renal outcomeshard clinical

Low-dose ramipril (1.25 mg/day) does not provide the cardiovascular and renal benefits observed with higher doses (10 mg/day) in patients with type 2 diabetes and albuminuria.

Abstract

Low dose (1.25 mg) ramipril once daily has no effect on cardiovascular and renal outcomes of patients with type 2 diabetes and albuminuria, despite a slight decrease in blood pressure and urinary albumin. The cardiovascular benefits of a daily higher dose (10 mg) ramipril observed elsewhere are not found with an eightfold lower daily dose.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Marre et al. (2004) studied this question.

synapsesocial.com/papers/69d570e575589c71d767dfdfhttps://doi.org/10.1136/bmj.37970.629537.0d
Ask AI
Helpful
Bookmark
Share
View Full Paper